glp-1 weight loss drug medications for GLP-1 medications for weight loss

The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

Blue Cross Blue Shield of Massachusetts will soon stop covering popular drugs for weight loss, like Ozempic.

Learn how to switch from tirzepatide to retatrutide safely

By Sabina Paglialunga, PhD & Aernout van Haarst, PhD Senior Directors Scientific Affairs Glucagon-Like Peptide-1 (GLP-1) receptor agonists first came to the market in 2005 as a type 2 diabetes mellitus treatment, and they have been making headlines again for their weight reduction effects

PlexusDx provides access to compounded semaglutide starting at $149/month through licensed pharmacies

Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity